Design and Processing of solid Dispersions in pharmaceutical Industry by Timpe, Carsten
Symposium on Pharmaceutical Engineering Research SPhERe, 25 – 27 September 2019, Braunschweig/Germany 1 
DESIGN AND PROCESSING OF SOLID 
DISPERSIONS IN PHARMACEUTICAL 
INDUSTRY 
Carsten Timpe 
F. Hoffmann La Roche AG, CH-4070 Basel,
Switzerland 
ABSTRACT 
Solid dispersions have already been described over more 
than 50 years ago in scientific literature to improve 
solubility of poorly water soluble drugs. With the 
increasing number of new poorly soluble drug 
candidates discovered at early industrial stages, the 
knowledge about these metastable amorphous systems 
has significantly improved over the decades. While in 
the early days of solid dispersions pharmaceutical 
companies were rather very reluctant to invest in 
corresponding manufacturing technologies, nowadays a 
significant number of market drug products has been 
developed based upon this not novel drug delivery 
principle. The presentation will give an overview about 
properties of solid dispersions, industrial screening and 
manufacturing methods and the biopharmaceutical 
implications. 
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INTRODUCTION 
With the dramatic increase in poorly soluble drug 
candidates (Biopharmaceutical Classes I and IV) from 
drug discovery organisations in industrial drug 
development, scientists had to look for innovative 
approaches to improve their aqueous and in-vivo 
solubilities. Beside salt formation, particle size 
reduction (e.g. milling, micro- or nano-nizing), 
formation of Cyclodextrin complexes or incorporation 
of poorly soluble drug candidates in microemulsion 
systems (SEDDS, SMEDDS), the destruction of the 
crystal lattice in a suitable matrix and thus formation of 
a metastable amorphous system or solid dispersion has 
in the meantime turned out to become one of the most 
attractive approaches in industrial drug development.  
RESEARCH CONCEPT 
Delivery principle 
The interest in solid dispersions has started in the 1960s 
already and a first definition was given by Chiou and 
Riegelmann: “ A solid dispersion is a dispersion of one 
or more active ingredients in an inert carrier or matrix 
by the melting (fusion), solvent, or the melting-solvent 
method [Chiou, Riegelmann, 1971]. With regards to the 
metastable nature of these ideally amorphous systems, 
the question that researchers had to solve was always the 
physical stability, preventing recrystallization of try at 
least to delay such an event until the end of the shelf-life 
of a marketed drug product. Such a stabilization could 
be a solubility, thermodynamically based concept or the 
formation of a solid dispersion where the dispersed 
molecules of the poorly soluble drug candidates are 
kinetically immobilized, e.g. by adjusting high glass 
transition temperatures for the solid dispersion using the 
principles described by the Gordon-Taylor equation 
with w1 and w2 representing the weight fractions e.g. of 
drug and matrix/polymer and Tg1 and Tg2 their 
corresponding glass transition temperatures (Tg is then 
the glass transition temperature of the solid dispersion). 
Gordon-Taylor equation 
 Equation 1 
Nowadays solid dispersions are divided into 3  different 
categories or generations – starting in the early daysof 
the 1st generation with crystalline carriers (e.g. Urea, 
Fructose), moving later to polymeric carrier based (2nd 
generation) and then more recently to those of the 3rd 
generation including surface active carrier types. 
Screening approaches 
Details about different types of amorphous systems will 
be discussed during the presentation and screening 
concepts discussed (e.g. solubility in liquids, use of 
Hansen solubility parameters, DSC technique, other 
methods). Supportive modern analytical technologies 
will be briefly mentioned (e.g. SEM, TEM; micro 
Raman technique [Karavas, Georgarakis, Docoslis, 
Bikiaris, 2007]., solid stage NMR 
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Manufacturing technologies 
Over the past decades a couple of different 
manufacturing technologies have been applied. 
Generally the most prominent approaches are either 
based upon melting (e.g. hot melt-extrusion HME) or 
solvent based (e.g. spray drying, spray granulation). 
During the presentation further technical details and a 
scale-up experiment will be discussed.. 
Biophamaceutical aspects 
An increase in aqueous solubility by forming a solid 
dispersion can improve drug absorption and thus the 
bioavailability of a poorly soluble drug significantly. 
Nevertheless it needs to be considered that vertain drugs 
have a high tendency to crush out or precipitate once the 
solid dispersion reaches the gastrointestinal tract. 
Therefore formulation scientists need to test solid 
dispersion prototype formulations also with regards to 
their precipitation robustness. Addition of surfactant-
type carriers might improve the robustness significantly. 
Also such aspects have to be routinely screened 
nowadays, 
RESULTS 
The examples provided during the presentation will 
demonstrate how to develop solid dispersions by 
screening the right formulations and selecting the right 
manufacturing technology at an industrial scale 
including scaling-up and  
DISCUSSION 
The presentation explains the evolution of solid 
dispersion formuations over the last 50 years and how it 
is possible nowadays to develop stable and better up-
scalable solid dispersions than ever before. 
CONCLUSIONS 
Solid dispersions are an attractive modern approach to 
deliver poorly soluble (“brickstone”) drugs successfully 
in an industrial environment. This has led to the market 
introduction of multiple products helping to 
significantly improve patients` lives. 
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NOMENCLATURE 
SEDDS      self-emulsifying drug delivery system 
SMEDDS  self-microemulsifying drug delivery system 
SEM          scanning electron microscopy 
TEM    transmission electron microscopy 
Tg        glass transition temperature 
W1, w2      weight fraction 
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